key: cord-0700835-uiw98ms8
authors: Lee, Wendy Wan Hui; Cheong, Yaw Kiet; Teh, Cheng Lay; Wan, Sharifah Aishah; Chuah, Seow Lin; Singh, Benjamin Sachdev Manjit
title: Impact of COVID-19 on hospitalization of patients with systemic lupus erythematosus (SLE)
date: 2021-09-11
journal: Clin Rheumatol
DOI: 10.1007/s10067-021-05920-3
sha: a792eb64cc6ca03cfb9984d1f71b347217433ede
doc_id: 700835
cord_uid: uiw98ms8

nan

Medical Research and Ethics Committee (MREC) (NMRR-19-2917-51,131 IIR). Clinical characteristics and outcomes of SLE hospitalizations were collected. The primary cause for hospitalization was determined by a physician based on a review of hospitalization records. Standard statistical methods were used to provide descriptive statistics. Cox regression analysis was used to determine the prognostic indicators of mortality in our patients.

A total of SLE admissions were steadily increasing over the years from 2016 to 2019, with a rapid increase from 2018 to 2019 (65.5%). The total number of SLE patients population in our center up to 31 December 2020 was 620. Interestingly, there is a significant decline (45.1%) in hospitalization in 2020, with an increase in the number of newly diagnosed cases during hospitalizations (n = 23 vs. n = 18) as illustrated in Table 1 . The most common reasons for hospitalization remained disease flare (61.5%) and infection (32.8%). There was only one SLE patient admitted for COVID-19 who was discharged well. There was a significant reduction of hospitalization for renal biopsy and renal-related procedures. There was no significant difference in the mean SLEDAI scores among the patients admitted for active SLE in 2020 compared to the previous years. However, there were three cases of severe lupus presenting with gastrointestinal manifestations (one pancreatitis, one superior mesenteric artery thrombosis, one lupus enteritis) and two cases of lupus myocarditis. The number of patients utilizing ICU care was the same as the previous year. Remarkably, the in-hospital mortality rate of SLE patients was higher in 2020 (10.7%) as compared to previous years (3.7-5.4%). The leading causes of death were flare and infection (6) , infection alone (3), and flare alone (3). One patient succumbed to an intracranial bleed. This expanded study reaffirmed our initial findings that the hospitalization rate among SLE patients declined in 2020 but was accompanied by an increase in morbidity and mortality rate [2] . Disease flare and infection remain the leading causes of admission and mortality among our SLE patients. Analysis using Cox regression showed that there were only two independent predictors of mortality, namely the presence of infection (HR 6.11) and age (HR 1.03). The increasing trend of SLE hospitalization over the years from 2016 to 2019 could be attributed to the expanding rheumatology service and the rising number of SLE referrals with the improvement of knowledge and awareness of SLE among general practitioners and physicians. This was however followed by a significant drop of SLE hospitalization in 2020 -the year of COVID-19 spread with its resulting impact on various aspects of life. There was only one SLE patient who was admitted with COVID-19, and she was discharged well. This concurred with the study by Espinosa G et al. [3] which showed that the incidence of COVID-19 is low in a cohort of SLE patients with stable and clinical inactive disease and all SLE patients with confirmed SARS-CoV-2 infection in their study recovered.

Measures instituted to mitigate the pandemic, such as lockdowns, rescheduling of non-urgent outpatient appointments, and the restructuring of medical care towards COVID-19, had limited patients' access to healthcare and disrupted routine medical care. These measures resulted in diagnostic delay and suboptimal medical care as forewarned by Horisberger et al. [4] . Routine care cancelations and difficulties in accessing healthcare also contributed to physical deterioration among patients with lupus [5] . Additionally, avoidance of care by patients due to fear of the pandemic had led to a higher risk of disease flare and severe illness at presentation. Furthermore, social determinants of health such as food security, income, and social isolation impose adverse psychosocial effects on patients during this pandemic [6, 7] . Although telemedicine has been widely used to replace physical clinic visits during this pandemic, it might be insufficient especially for patients with SLE, as close monitoring of both clinical and laboratory parameters is essential in the detection of flares and deterioration. Fernandez-Ruiz R et al. [8] highlighted that patients with SLE require routine monitoring of laboratory parameters and that new patients or those with urgent concerns may require a more thorough evaluation than what is feasible by telemedicine.

Our study showed that the rate of SLE hospitalization declined during this pandemic, but it was accompanied by an increased mortality rate due to measures implemented to mitigate the pandemic. As our hospital was a designated COVID-19 hospital, our data has its inherent selection bias. Further studies are needed to ascertain the impact of COVID-19 on the pattern of hospitalization among SLE patients worldwide. Nevertheless, special attention must be given to our vulnerable population of patients when implementing new measures to curb the pandemic. All this is in the hope of delivering more effective healthcare for our patients during this current pandemic and in preparation for future health crises.

Sarawak state disaster management committee initiative website

Impact of COVID-19 pandemic on hospitalisation of patients with systemic lupus erythematosus (SLE): report from a tertiary hospital during the peak of the pandemic. Ann Rheum Dis annrheumdis-2020-218475

The impact of SARS-CoV-2 coronavirus infection in patients with systemic lupus erythematosus from a single center in Catalonia

Impact of COVID-19 pandemic on SLE: beyond the risk of infection

The impact of the COVID-19 pandemic on the medical care and health-care behaviour of patients with lupus and other systemic autoimmune diseases: a mixed methods longitudinal study

Impact of the COVID-19 pandemic on patients with systemic lupus erythematosus: observations from an Indian inception cohort

Impact of COVID-19 on vulnerable patients with rheumatic disease: results of a worldwide survey

COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease

The authors would like to thank the Director General of Health, Malaysia, for permission to publish this article.Author contribution Lee WWH analyzed data, did the literature search and wrote the manuscript. Cheong YK acquired the data and wrote the manuscript. Teh CL conceived the study, analyzed data, and critically revised the manuscript. Wan SA, Chuah SL, and Sachdev Manjit Singh B acquired the data and critically revised the manuscript. All authors approved the final version of the paper.Data availability All data generated or analyzed during this study are included in this published article.

Disclosures None.